Bolt Biotherapeutics, Inc. (BOLT) News
Follow Bolt Biotherapeutics, Inc. (BOLT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Bolt Biotherapeutics Completes Prana Acquisition and Raises $120 Million
Bolt completed its stock-for-stock acquisition of Prana Therapies in October and closed a concurrent $120 million private placement. Prana’s PRA-216 is in Phase 2 across asthma, COPD and atopic dermatitis; a fourth study
MNA | Nov 12, 2026, 09:12 PM UTC
M
Bolt Biotherapeutics Acquires Prana Therapies in Reverse Merger, Secures USD 120 Million Financing
Bolt Biotherapeutics is acquiring Prana Therapies in a reverse merger and securing USD 120 million in financing.
EQUITY | Oct 28, 2026, 04:40 PM UTC
M
Bolt Biotherapeutics Completes Prana Merger and $120 Million Financing
Bolt completed its merger with Prana Therapies on October 23, issuing Prana equityholders common and Series D preferred shares. Bolt also agreed to sell $120 million of preferred shares and warrants in a private placemen
MNA | Oct 23, 2026, 02:33 PM UTC
M
Bolt Biotherapeutics to Acquire Prana Therapies, Raises $120 Million in Private Placement
Bolt announced the acquisition of Prana Therapies and a concurrent $120 million private placement to advance PRA-216 in inflammatory indications.
EQUITY | Oct 23, 2026, 01:14 PM UTC
M
Bolt Biotherapeutics to Acquire Prana Therapies, Raises $120 Million
Bolt Biotherapeutics announced the acquisition of Prana Therapies and a concurrent $120 million private placement to advance PRA-216 in inflammatory indications.
EQUITY | Oct 23, 2026, 01:08 PM UTC
L
Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate
Bolt Biotherapeutics (NASDAQ: BOLT ) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per shar
EARNINGS | Aug 11, 2026, 08:20 PM UTC
L
BOLT - Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
BOLT - Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 11, 2026, 08:07 PM UTC